JP2006511484A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511484A5
JP2006511484A5 JP2004543510A JP2004543510A JP2006511484A5 JP 2006511484 A5 JP2006511484 A5 JP 2006511484A5 JP 2004543510 A JP2004543510 A JP 2004543510A JP 2004543510 A JP2004543510 A JP 2004543510A JP 2006511484 A5 JP2006511484 A5 JP 2006511484A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
group
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004543510A
Other languages
English (en)
Japanese (ja)
Other versions
JP4515911B2 (ja
JP2006511484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031844 external-priority patent/WO2004033422A2/en
Publication of JP2006511484A publication Critical patent/JP2006511484A/ja
Publication of JP2006511484A5 publication Critical patent/JP2006511484A5/ja
Application granted granted Critical
Publication of JP4515911B2 publication Critical patent/JP4515911B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004543510A 2002-10-07 2003-10-07 アナンダミド加水分解の遮断による不安の調節 Expired - Fee Related JP4515911B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41700802P 2002-10-07 2002-10-07
PCT/US2003/031844 WO2004033422A2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Publications (3)

Publication Number Publication Date
JP2006511484A JP2006511484A (ja) 2006-04-06
JP2006511484A5 true JP2006511484A5 (https=) 2006-11-24
JP4515911B2 JP4515911B2 (ja) 2010-08-04

Family

ID=32093946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004543510A Expired - Fee Related JP4515911B2 (ja) 2002-10-07 2003-10-07 アナンダミド加水分解の遮断による不安の調節

Country Status (11)

Country Link
US (3) US7176201B2 (https=)
EP (1) EP1558591B1 (https=)
JP (1) JP4515911B2 (https=)
KR (1) KR20050088992A (https=)
CN (1) CN100408556C (https=)
AU (1) AU2003279877B2 (https=)
CA (1) CA2501506C (https=)
EA (1) EA010267B1 (https=)
MX (1) MXPA05003715A (https=)
UA (1) UA80841C2 (https=)
WO (1) WO2004033422A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
EA010267B1 (ru) * 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида
US20050026844A1 (en) * 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
JP2007509066A (ja) * 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
PL1761480T3 (pl) * 2004-06-23 2009-07-31 Hoffmann La Roche Inhibitory mao-b
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
WO2006058088A2 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
TWI385164B (zh) * 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
MX2008008529A (es) * 2005-12-29 2008-09-26 Organon Nv Inhibidores de amida hidrolasa de acido graso.
WO2007106706A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders
WO2007140005A2 (en) * 2006-05-26 2007-12-06 Janssen Pharmaceutica N.V. Oxazolyl piperidine modulators of fatty acid amide hydrolase
WO2008021625A2 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) * 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
CA2674359A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
DE102007022007A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
US8372823B2 (en) 2007-05-25 2013-02-12 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
CA2689148A1 (en) * 2007-05-31 2008-12-11 The Scripps Research Institute Tricyclic inhibitors of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
TWI434842B (zh) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
JPWO2010053120A1 (ja) 2008-11-06 2012-04-05 アステラス製薬株式会社 カルバメート化合物又はその塩
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
MX342128B (es) * 2008-12-24 2016-09-14 Bial - Portela & C A S A Compuestos farmaceuticos.
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US8735406B2 (en) 2009-09-09 2014-05-27 Dainippon Sumitomo Pharma Co., Ltd. 8-oxodihydropurine derivative
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
CA2787476C (en) * 2010-01-20 2017-07-11 Sanofi Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
EP2593078B1 (en) 2010-05-25 2016-11-30 Symrise AG Cyclohexyl carbamate compounds as active anti-cellulite ingredients
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
BR112012029961B1 (pt) * 2010-05-25 2017-06-06 Symrise Ag compostos de carbamato de ciclo-hexila, seus usos, composições cosméticas e métodos cosméticos para clareamento da pele e/ou cabelo
US9187413B2 (en) 2010-07-28 2015-11-17 The Regents Of The University Of California Peripherally restricted FAAH inhibitors
EP2433527B1 (en) * 2010-09-28 2013-04-03 Gruppo Cimbali S.p.A. Improved automatic milk frothing wand
KR102079404B1 (ko) * 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
RU2693457C2 (ru) * 2013-07-18 2019-07-03 Фондацьоне Иституто Итальяно Ди Текнолоджия Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr)
AR100387A1 (es) * 2014-02-18 2016-10-05 Basf Se Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EP3381995B1 (en) 2015-12-11 2019-10-23 National University Corporation Shizuoka University Oil-gelling agent
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
EP3762034B1 (en) 2018-03-05 2025-08-27 Wylder Nation Foundation A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
US20240180905A1 (en) * 2020-07-21 2024-06-06 Neuritek Ltd. Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders
WO2025015420A1 (en) * 2023-07-17 2025-01-23 Apogee Pharmaceuticals, Inc. Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531554A (https=) * 1953-09-02
US3084096A (en) * 1955-08-29 1963-04-02 Union Carbide Corp Indanyl n-methyl carbamate
US3275512A (en) * 1962-11-27 1966-09-27 Upjohn Co Process for treating inflammation with biphenylcarbamates
US3632631A (en) * 1967-09-08 1972-01-04 Ethyl Corp Sterically hindered bisphenyl carbamates
US3880908A (en) * 1972-01-24 1975-04-29 Standard Oil Co Urethane derivatives of polymethyl biphenyl useful as fungicides
DE2943480A1 (de) 1979-10-27 1981-05-07 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten
HU197831B (en) 1984-12-20 1989-06-28 Chinoin Gyogyszer Es Vegyeszet Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
JPS63303661A (ja) 1987-01-22 1988-12-12 Ishikawajima Harima Heavy Ind Co Ltd 注湯装置
US4987233A (en) 1988-06-15 1991-01-22 Eli Lilly And Company Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives
IL95994A0 (en) 1989-11-15 1991-07-18 American Home Prod Carbamate esters and pharmaceutical compositions containing them
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
DE4430600A1 (de) 1994-08-22 1996-02-29 Hoechst Schering Agrevo Gmbh Biphenyl-Derivate
JPH0892167A (ja) * 1994-09-21 1996-04-09 Idemitsu Kosan Co Ltd 芳香族炭酸ジエステルの製造方法
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) * 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
SI20018A (sl) 1996-11-19 2000-02-29 Icn Pharmaceuticals, Inc. Večvalentne soli piridostigmina in sorodnih spojin
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6251931B1 (en) * 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
KR100613196B1 (ko) 2000-07-19 2006-08-18 에프. 호프만-라 로슈 아게 메탈로프로테아제 억제제로서의 피롤리딘 유도체
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
CZ2003451A3 (cs) 2000-08-16 2003-10-15 F. Hoffmann-La Roche Ag Nové deriváty aminocyklohexanu
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
US6562846B2 (en) * 2001-04-27 2003-05-13 Bristol-Myers Squibb Company Bisarylimidazolyl fatty acid amide hydrolase inhibitors
EP1458374A2 (en) 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US6949574B2 (en) * 2002-02-08 2005-09-27 Bristol-Myers Squibb Company (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EA010267B1 (ru) 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида

Similar Documents

Publication Publication Date Title
JP2006511484A5 (https=)
RU2001104339A (ru) Производные тиобензимидазола
JP2002536445A5 (https=)
RU2007101685A (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2003137578A (ru) Производные ароматических дикарбоновых кислот
JP2005519932A5 (https=)
JP2004525117A5 (https=)
RU2011112393A (ru) 8-замещенные производные изохинолина и их применение
JP2005508962A5 (https=)
RU2014122340A (ru) Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент {2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил}амина
SE0104330D0 (sv) Therapeutic agents
RU2005110061A (ru) Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина
RU2004106555A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
JP2016506387A5 (https=)
CY1110593T1 (el) Η χρηση φαρμακευτικης συνθεσης που περιεχει παραγωγο παρα - αμινοφαινυλοξικου οξεος για τη θεραπεια των φλεγμονωδων καταστασεων του γαστρεντερικου σωληνα
JP2009526865A5 (https=)
JP2007516180A5 (https=)
JP2008526999A5 (https=)
JP2007246474A5 (https=)
RU2005123401A (ru) Ароматические соединения как противовоспалительные, иммуномодулирующие и антипролиферативные средства
RU2003120069A (ru) Замещенные 2-анилино-бензимидазолы, их применение в качестве ингибиторов na+/h+-обмена, а также содержащее их лекарственное средство
RU2012133250A (ru) Производные прегнана, конденсированные в положении 16, 17 с пирролидиновым циклом, обладающие глюкокортикоидной активностью
CA2612176A1 (en) Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
RU2005129550A (ru) Антагонисты рецептора ccr-3
RU2009128970A (ru) Производные изосорбидмононитрата для лечения кишечных заболеваний